Journal article
Revised MALT‐IPI : A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma
American journal of hematology, Vol.97(12), pp.1529-1537
12/2022
DOI: 10.1002/ajh.26715
PMCID: PMC9847507
PMID: 36057138
Abstract
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the “Revised mucosa-associated lymphoid tissue International Prognostic Index” (Revised MALT-IPI) in a large data set (n = 397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n = 297) and from IELSG-19 study (n = 400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT-IPI has scores ranging from 0 to 5, calculated as a sum of one point for each of the following- age >60 years, elevated LDH, and stage III–IV; and two points for MMS. In the training cohort, the Revised MALT-IPI defined four risk groups: low risk (score 0, reference group), low-medium risk (score 1, HR = 1.85, p =.008), medium-high risk (score 2, HR = 3.84, p <.0001), and high risk (score 3+, HR = 8.48, p <.0001). Performance of the Revised MALT-IPI was similar in external validation cohorts. Revised MALT-IPI is a new index centered on disease characteristics that provides robust risk-stratification identifying a group of patients characterized by earlier progression of disease. Revised MALT-IPI can allow a more disease-adjusted management of patients with EMZL in clinical trials and practice.
Details
- Title: Subtitle
- Revised MALT‐IPI : A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma
- Creators
- Juan Pablo Alderuccio - Sylvester Comprehensive Cancer CenterIsildinha M. Reis - University of MiamiThomas M. Habermann - Mayo ClinicBrian K. Link - University of IowaCatherine Thieblemont - Hôpital Saint-LouisAnnarita Conconi - Ospedale degli InfermiMelissa C. Larson - Mayo Clinic in FloridaLuciano Cascione - Ente Ospedaliero CantonaleWei Zhao - Sylvester Comprehensive Cancer CenterJames R. Cerhan - Mayo Clinic in FloridaEmanuele Zucca - Ente Ospedaliero CantonaleIzidore S. Lossos - Sylvester Comprehensive Cancer Center
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.97(12), pp.1529-1537
- DOI
- 10.1002/ajh.26715
- PMID
- 36057138
- PMCID
- PMC9847507
- NLM abbreviation
- Am J Hematol
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Grant note
- DOI: 10.13039/100000054, name: National Cancer Institute, award: P30 CA240139, P50 CA97274, U01 CA195568, 1R01CA233945
- Language
- English
- Date published
- 12/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984359824602771
Metrics
18 Record Views